442526-87-6|ABT-510 acetate|(S)-N-ethyl-1-(((S)-2-((2S,3R)-3-hydroxy-2-((2R,3S)-3-methyl-2-((S)-3-methyl-2-(2-(2-(N-methylacetamido)acetamido)acetamido)butanamido)pentanamido)butanamido)pentanoyl)-L-isoleucyl-L-arginyl)pyrrolidine-2-carboxamide acetate|-范德生物科技公司

ABT-510 acetate

NMR下载 COA and HPLC MSDS下载
names：
(S)-N-ethyl-1-(((S)-2-((2S,3R)-3-hydroxy-2-((2R,3S)-3-methyl-2-((S)-3-methyl-2-(2-(2-(N-methylacetamido)acetamido)acetamido)butanamido)pentanamido)butanamido)pentanoyl)-L-isoleucyl-L-arginyl)pyrrolidine-2-carboxamide acetate
CAS号：
442526-87-6
MDL Number：
MF(分子式)： C48H87N13O13 MW(分子量)： 1054.3
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	ABT-510 acetate
英文别名	ABT-510 acetate; ABT 510 acetate; ABT510 acetate;
CAS号	442526-87-6
SMILES	O=C(NCC)[C@H]1N(C([C@H](CCCNC(N)=N)NC([C@H]([C@@H](C)CC)NC([C@H](CCC)NC([C@H]([C@H](O)C)NC([C@@H]([C@@H](C)CC)NC([C@H](C(C)C)NC(CNC(CN(C(C)=O)C)=O)=O)=O)=O)=O)=O)=O)=O)CCC1.CC(O)=O
Inchi	InChI=1S/C46H83N13O11.C2H4O2/c1-12-18-30(39(64)55-36(26(7)13-2)42(67)53-31(19-16-21-50-46(47)48)45(70)59-22-17-20-32(59)40(65)49-15-4)52-44(69)38(28(9)60)57-43(68)37(27(8)14-3)56-41(66)35(25(5)6)54-33(62)23-51-34(63)24-58(11)29(10)61;1-2(3)4/h25-28,30-32,35-38,60H,12-24H2,1-11H3,(H,49,65)(H,51,63)(H,52,69)(H,53,67)(H,54,62)(H,55,64)(H,56,66)(H,57,68)(H4,47,48,50);1H3,(H,3,4)/t26-,27-,28+,30-,31-,32-,35-,36-,37+,38-;/m0./s1
InchiKey	VNYUZURIJSGETB-WVDYPPGZSA-N
分子式 Formula	C48H87N13O13
分子量 Molecular Weight	1054.3
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	ABT-510 acetate(CAS:442526-87-6):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	ABT-510 acetate is a synthetic analog of thrombospondin, an endogenous angiogenesis inhibitor.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Uronis HE, Cushman SM, Bendell JC, Blobe GC, Morse MA, Nixon AB, Dellinger A, Starr MD, Li H, Meadows K, Gockerman J, Pang H, Hurwitz HI. A phase I study of ABT-510 plus bevacizumab in advanced solid tumors. Cancer Med. 2013 Jun;2(3):316-24. doi: 10.1002/cam4.65. Epub 2013 Mar 2[1]PubMed PMID: 23930208; PubMed Central PMCID: PMC3699843.

[2]Matsumoto E, Fujita Y, Okada Y, Kauppinen EI, Kamiya H, Chiba K. Hydrophobic benzyl amines as supports for liquid-phase C-terminal amidated peptide synthesis: application to the preparation of ABT-510. J Pept Sci. 2015 Sep;21(9):691-5. doi: 10.1002/psc.2791. Epub 2015 Jul 22. PubMed PMID: 26200065.

[3] Recouvreux MV, Camilletti MA, Rifkin DB, Becu-Villalobos D, Díaz-Torga G. Thrombospondin-1 (TSP-1) analogs ABT-510 and ABT-898 inhibit prolactinoma growth and recover active pituitary transforming growth factor-β1 (TGF-β1). Endocrinology. 2012 Aug;153(8):3861-71. doi: 10.1210/en.2012-1007. Epub 2012 Jun 14. PubMed PMID: 22700773; PubMed Central PMCID: PMC3404347.

[4] Sahora AI, Rusk AW, Henkin J, McKeegan EM, Shi Y, Khanna C. Prospective study of thrombospondin-1 mimetic peptides, ABT-510 and ABT-898, in dogs with soft tissue sarcoma. J Vet Intern Med. 2012 Sep-Oct;26(5):1169-76. doi: 10.1111/j.1939-1676.2012.00966.x. Epub 2012 Jul 21. PubMed PMID: 22816494.

[5] Ebbinghaus S, Hussain M, Tannir N, Gordon M, Desai AA, Knight RA, Humerickhouse RA, Qian J, Gordon GB, Figlin R. Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma. Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6689-95. PubMed PMID: 18006769.

6: Markovic SN, Suman VJ, Rao RA, Ingle JN, Kaur JS, Erickson LA, Pitot HC, Croghan GA, McWilliams RR, Merchan J, Kottschade LA, Nevala WK, Uhl CB, Allred J, Creagan ET. A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. Am J Clin Oncol. 2007 Jun;30(3):303-9. PubMed PMID: 17551310.7: Campbell NE, Greenaway J, Henkin J, Moorehead RA, Petrik J. The thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer. Neoplasia. 2010 Mar;12(3):275-83. PubMed PMID: 20234821; PubMed Central PMCID: PMC2838444.8: Nabors LB, Fiveash JB, Markert JM, Kekan MS, Gillespie GY, Huang Z, Johnson MJ, Meleth S, Kuo H, Gladson CL, Fathallah-Shaykh HM. A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. Arch Neurol. 2010 Mar;67(3):313-9. doi: 10.1001/archneurol.2010.16. PubMed PMID: 20212229.9: Rusk A, McKeegan E, Haviv F, Majest S, Henkin J, Khanna C. Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers. Clin Cancer Res. 2006 Dec 15;12(24):7444-55. PubMed PMID: 17189418.10: Hoekstra R, de Vos FY, Eskens FA, de Vries EG, Uges DR, Knight R, Carr RA, Humerickhouse R, Verweij J, Gietema JA. Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: a safe combination. Eur J Cancer. 2006 Mar;42(4):467-72. Epub 2006 Jan 10. PubMed PMID: 16406507.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开